Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iodine I 131 tositumomab

Drug Profile

Iodine I 131 tositumomab

Alternative Names: 131-I-anti-B1 antibody; 131-I-tositumomab; Anti-CD20 murine monoclonal antibody-I-131; B1; Bexxar; I-131 anti-B1 antibody; Iodine 131 tositumomab; Iodine-131 anti-B1 antibody; Tositumomab; TST/I131-TST

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Corixa Corp
  • Developer GlaxoSmithKline
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Apoptosis stimulants; Immunostimulants; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Market Withdrawal Non-Hodgkin's lymphoma
  • Discontinued Mantle-cell lymphoma

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 20 Feb 2014 Withdrawn for Non-Hodgkin's lymphoma (Refractory metastatic disease) in USA and Canada (IV)
  • 07 Aug 2013 GlaxoSmithKline announces intention to withdraw iodine I 131 tositumomab (Barrax®) from the market in USA and Canada on 20 February 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top